ProCE Banner Activity

Osimertinib: A New EGFR Inhibitor to Overcome Acquired Resistance in Advanced NSCLC

Clinical Thought
With the approval of the third-generation EGFR TKI osimertinib, clinicians now have a treatment option for many patients with advanced NSCLC who develop resistance to first-line EGFR TKI therapy.

Released: April 29, 2016

Expiration: April 28, 2017

No longer available for credit.

Share

Faculty

Suresh S. Ramalingam

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Boehringer Ingelheim

Genentech BioOncology

Lilly

Novartis Oncology

Faculty Disclosure

Primary Author

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

Suresh S. Ramalingam, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Novartis.